DarioHealth Publishes Research Confirming the Impact of a Digital Therapeutic Platform and Live Coaching on Diabetes Outcomes
DarioHealth Corp. (Nasdaq: DRIO) announced a new study on its digital therapeutics for Type 2 diabetes published in the Journal of Diabetes Science and Technology. The study showed a 2.0% reduction in average HbA1c values among participants using the Dario app alongside certified coaching. Other notable findings included an 18% reduction in fasting blood glucose and a 10% reduction in BMI. The research highlights the effectiveness of combining digital self-monitoring with live coaching, supporting Dario's mission to enhance diabetes management.
- 2.0% reduction in average HbA1c lab values.
- 18% reduction in fasting blood glucose levels.
- 10% reduction in Body Mass Index (BMI).
- Significant improvement in glucose variability and self-reported satisfaction.
- None.
NEW YORK,, May 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced the publication of a new study through a Letter to the Editor in the Journal of Diabetes Science and Technology. The study is titled "Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring."
People living with Type 2 diabetes have complicated self-care requirements that can make better health difficult to achieve. Although consumers have access to a wide variety of digital and app-based diabetes management tools, there is little clinical and self-reported evidence demonstrating the effectiveness of digital self-monitoring combined with coaching.
In this new study, participants using Dario's digital therapeutics for diabetes management were monitored for both clinical and self-reported impact. Over a period of three months, participants tracked blood glucose levels in the Dario app and worked with a live Certified Diabetes Care and Education Specialist (CDCES), leading to demonstrated clinically significant improvements on lab test results, platform-based data and self-reported data.
This new research presents several key clinical data points:
2.0% reduction in average HbA1c lab values for participants- Significant reduction in additional lab values such as Fasting Blood Glucose (
18% ) and Body Mass Index (BMI) (10% ) - Statistically significant improvement in glucose variability
- Significant improvement in self-reported evaluation in weight and glucose control satisfaction
Further interaction analysis also indicated participant's engagement with a CDCES served to predict positive reductions in glucose variability in the following week, adding additional understanding of the impact of live coaching as a complement to digital self-monitoring.
"This clinical study re-confirms the persistent and substantial estimated HbA1c reductions we see in our other studies by demonstrating actual HbA1c reductions. The present study, while small, demonstrated a robust
"These findings add valuable data to the little-understood application of digital self-monitoring and coaching in diabetes management," said Yifat Hershcovitz, Ph.D., Scientific and Clinical Director at DarioHealth. "Our findings provide clinical validation for digital self-monitoring to deliver personalized care alongside access to a live coach. The study demonstrates our data-driven technology is working for people with type 2 diabetes, guiding them in making effective decisions in diabetes management."
This new research complements recent research by Dario published in the Journal of Medical Internet Research on the subject of engagement and sustained behavior change, adding to the company's growing intelligence of how highly personalized digital therapeutics can be most effectively deployed to improve health and outcomes.
This article, "Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring", by Yifat Hershcovitz, PhD., and published in Journal of Diabetes Science and Technology, will be free to access for a limited time and can be read here.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario's next-generation, AI-powered, digital therapeutic solutions support more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users' health. Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the study findings and that the study findings add valuable data to the little-understood application of digital self-monitoring and coaching in diabetes management. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social, and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220
Investor Relations Contact:
Chuck Padala
chuck@lifesciadvisors.com
+1-646-627-8390
Media Contact:
Josephine Galatioto
Josephine.galatioto@russopartnersllc.com
+1-212-845-4262
Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg
View original content:http://www.prnewswire.com/news-releases/dariohealth-publishes-research-confirming-the-impact-of-a-digital-therapeutic-platform-and-live-coaching-on-diabetes-outcomes-301300829.html
SOURCE DarioHealth Corp.
